Advances in the Development of SARS-CoV-2 Mpro Inhibitors
![Thumbnail](/xmlui/bitstream/handle/10234/199927/Agost_2022_Advances.pdf.jpg?sequence=4&isAllowed=y)
Visualitza/
Impacte
![Google Scholar](/xmlui/themes/Mirage2/images/uji/logo_google.png)
![Microsoft Academico](/xmlui/themes/Mirage2/images/uji/logo_microsoft.png)
Metadades
Mostra el registre complet de l'elementcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/7053
comunitat-uji-handle3:10234/8639
comunitat-uji-handle4:
INVESTIGACIONMetadades
Títol
Advances in the Development of SARS-CoV-2 Mpro InhibitorsAutoria
Data de publicació
2022-04-14Editor
MDPIISSN
1420-3049Cita bibliogràfica
Agost-Beltrán, L.; de la Hoz-Rodríguez, S.; Bou-Iserte, L.; Rodríguez, S.; Fernández-de-la-Pradilla, A.; González, F.V. Advances in the Development of SARS-CoV-2 Mpro Inhibitors. Molecules 2022, 27, 2523. https://doi.org/10.3390/molecules 27082523Tipus de document
info:eu-repo/semantics/articleVersió
info:eu-repo/semantics/publishedVersionParaules clau / Matèries
Resum
Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been
to find inhibitors of the main protease (Mpro) of the virus SARS-CoV-2. Initially, previously reported
inhibitors of related ... [+]
Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been
to find inhibitors of the main protease (Mpro) of the virus SARS-CoV-2. Initially, previously reported
inhibitors of related proteases such as the main proteases of SARS-CoV and MERS-CoV were tested.
A huge effort was then carried out by the scientific community to design, synthesize and test new
small molecules acting as inactivators of SARS-CoV-2 Mpro. From the chemical structure view, these
compounds can be classified into two main groups: one corresponds to modified peptides displaying
an adequate sequence for high affinity and a reactive warhead; and the second is a diverse group
including chemical compounds that do not have a peptide framework. Although a drug including a
SARS-CoV-2 main protease inhibitor has already been commercialized, denoting the importance of
this field, more compounds have been demonstrated to be promising potent inhibitors as potential
antiviral drugs. [-]
Publicat a
Molecules, Vol. 27, Iss. 8 (April-2 2022)Entitat finançadora
Universitat Jaume I | Ministerio de Universidades
Codi del projecte o subvenció
UJI‐2021-71 | FPU19/04913 | FPU17/06209 | FPU20/03516
Títol del projecte o subvenció
SomUJIContraCovid
Drets d'accés
info:eu-repo/semantics/openAccess
Apareix a les col.leccions
- QFA_Articles [819]
- QUIO_Articles [695]
Except where otherwise noted, this item's license is described as Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).